Bicara Therapeutics Inc. (NasdaqGM: BCAX)
Health Care · Biotechnology · US
$17.50
-0.74% today · -5.5% 1Y
Bicara Therapeutics Inc. (NasdaqGM: BCAX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.16B and employs 103 people.
Over the last twelve months the share price has lost 5.5%, trading between 13.70 and 30.99.
Tweenvest scores Bicara Therapeutics Inc. across four factors: quality 52/100, value 44/100. Its strongest factor is quality.
BCAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.16B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.11
- Dividend yield
- —
- Beta (5Y)
- -0.69
- 52-week high
- $30.99
- 52-week low
- $13.70
- Avg volume (3M)
- —
- Shares outstanding
- 66.17M
- Employees
- 103
- Next earnings
- —
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
- ISIN
- US0554771032
- Founded
- 2018
- Listed since
- Sep 13, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vor Biopharma Inc.NasdaqGS: VOR | $1.18B | $19.90 | +6.47% |
| NatureCell Co.,Ltd.KOSDAQ: A007390 | $1.18B | ₩24,550.00 | -0.81% |
| HBM Holdings LimitedSEHK: 2142 | $1.17B | HK$11.14 | -17.11% |
| Aimed Bio Inc.KOSDAQ: A0009K0 | $1.17B | ₩24,250.00 | -2.22% |
| Amoy Diagnostics Co., Ltd.SZSE: 300685 | $1.16B | CN¥20.30 | -4.87% |
| Nanjing Leads Biolabs Co., Ltd.SEHK: 9887 | $1.13B | HK$45.56 | -9.69% |
| L&C BIO Co.,LTDKOSDAQ: A290650 | $1.13B | ₩56,400.00 | +5.03% |
| Janux Therapeutics, Inc.NasdaqGM: JANX | $1.12B | $18.39 | +8.62% |
Figures last refreshed Oct 11, 2026.